Tuesday, October 22, 2019 3:13:07 PM
If you’re on the hunt for stocks to watch today, Xenetic Biosciences, Inc. (NASDAQ:XBIO) is a stock to give close attention to. The company shares are trading 10.84% or 0.18 points down from last closing price of $1.66, reaching $1.48 at last check. The XBIO share price has dropped in 2 of the last 5 days and is down -39.86% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -1,446,375 shares, and in total 663825 shares valued at $982461 were seen changing hands compared with 2.11 million shares valued at $3.503 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the XBIO stock is near its bottom.
Xenetic Biosciences, Inc. (XBIO) shares have notched a 3-month decline of about -39.86%, but has still tumbled -91.57% year to date. By comparison, the stock sank -94.78% over the past 12 months, while it jumped 15.28% over the 1 month. The company’s market cap is around $6.82M, with its short interest ratio standing at 0.09%.
In the current trading session for XBIO, the stock witnessed two major price actions, it rose to a high of $1.7 and was down as much as $1.46 at one point. The high recorded is very low when compared to their 52-week high which is $0.99. The 52-week high is now at -96.58 distance from current price. Their recent low of $44.4 represents a 53.07% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for XBIO is $10, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
XBIO‘s last price was down -87.89% as compared to the average trading price of 50 days recorded at $12.22 while enlarging the period to 200 trading days, the average closing price was $1.45. At present, there are 4.11 million in the total number of common shares owned by the public and among those 2.77 million shares have been available to trade. The percentage of shares being held by the company management was 7.5% while institutions stake was 30.3%. The company has generated negative returns on equity over the last 12 months (-93.1%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the XBIO stock, there is another set of technicals that should be looked into and considered. Its 24.6% gain from moving average of $1.19 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 2.53 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
In the last five years, the EPS of the company has been roughly 19.4%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.
Recent XBIO News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:00:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:32:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 02:15:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 10:18:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 10:16:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:30:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:30:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 10:00:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/13/2023 10:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:30:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:00:42 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM